Oncology – Page 5

Rising Waiting Times for Cancer Surgery in the US: National Trends, Predictors, and Implications for Care Delivery

By MedXY 08/16/2026

Since 2012, waiting times from diagnosis to first cancer surgery have significantly increased across major US cancers, disproportionately affecting vulnerable populations and high-volume academic centers, underscoring urgent need for system-level interventions.

news OB/GYN & Women’s Health Oncology

Understanding Persistent Low-Level hCG Post-GTD: Natural History and Predictive Factors for Gestational Trophoblastic Neoplasia

By MedXY 08/16/2026

Persistent low-level hCG following gestational trophoblastic disease often resolves spontaneously. Key clinical and biochemical predictors can identify patients at higher risk for subsequent neoplasia, guiding optimal surveillance.

Diabetes & Endocrinology news Oncology

Thermal Ablation for Low-Risk Papillary Thyroid Cancer in Latin America: Promising Early Outcomes from a Multicenter Study

By MedXY 08/15/2026

A large Latin American study shows radiofrequency ablation is a safe, effective minimally invasive alternative for T1a low-risk papillary thyroid cancer, with excellent tumor disappearance rates and minimal complications over 18 months follow-up.

Diabetes & Endocrinology news Oncology

Metabolic Dysfunction Following Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer: Clinical Implications and Risks

By MedXY 08/15/2026

This study reveals a significant early onset of metabolic syndrome in men with prostate cancer treated with combined ADT and ARPI therapies, highlighting the necessity for multidisciplinary metabolic monitoring and interventions.

news Oncology Urology

Systemic Therapy for Metastatic Castration-Resistant Prostate Cancer: Key Recommendations from the ASCO Living Guideline (Version 2026.1.4)

By MedXY 08/14/2026

A clear, practice-focused summary of the 2026 ASCO living guideline on systemic treatment of metastatic castration‑resistant prostate cancer, emphasizing biomarker-driven choices, sequencing, and new options such as 177Lu‑PSMA and PARP inhibitors.

news Oncology Otorhinolaryngology

Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma: Promising Efficacy Across HER2 Expression Levels

By MedXY 08/14/2026

This phase II trial demonstrates significant antitumor activity of trastuzumab rezetecan in both HER2-high and HER2-low advanced salivary gland carcinoma with a manageable safety profile, offering new hope for this challenging malignancy.

news OB/GYN & Women’s Health Oncology

Revisiting HER2 Status in Recurrent Cervical Cancer: Clinical Implications of Dynamic Expression for Targeted Therapy

By MedXY 08/14/2026

HER2 expression in recurrent cervical cancer varies notably by histology and recurrence site, underscoring the importance of reassessment to guide HER2-targeted treatments effectively.

General Surgery news Oncology

Long-Term Survival and Curative Potential of Liver Transplantation for Nonresectable Colorectal Liver Metastases: Insights from the SECA-II Study

By MedXY 08/14/2026

A decade-long follow-up of the SECA-II study demonstrates that liver transplantation in highly selected patients with nonresectable colorectal liver-only metastases yields substantial long-term survival and may offer curative potential even after relapse.

General Surgery news Oncology

Resection Extent in Non-Small Cell Lung Cancer: Margin Positivity is Unrelated to Surgical Scope

By MedXY 08/14/2026

A recent study demonstrates that positive surgical margins in non-small cell lung cancer (NSCLC) do not vary significantly with resection type, supporting selective use of wedge resection without compromising oncologic outcomes.

Dermatology news Oncology

Neoadjuvant Intralesional Daromun Significantly Improves Outcomes in Resectable Stage III Melanoma: Insights from the PIVOTAL Phase III Trial Update

By MedXY 08/13/2026

Updated PIVOTAL Phase III trial data demonstrate that neoadjuvant intralesional Daromun significantly improves recurrence-free and distant metastasis-free survival in resectable stage III melanoma without new safety concerns at 36.8 months median follow-up.

Neurology news Oncology

Reevaluating Age as a Prognostic Marker in Molecularly Defined Lower-Grade Gliomas

By MedXY 08/13/2026

This article examines how age, traditionally considered a high-risk factor in lower-grade gliomas, influences prognosis and treatment decisions in the molecular era, highlighting the importance of IDH mutation status.

Dermatology news Oncology

Long-Term Survival Benefit of Spartalizumab with Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma: Insights from the COMBI-I Trial

By MedXY 08/13/2026

The COMBI-I trial demonstrates that adding spartalizumab to dabrafenib and trametinib improves overall survival in patients with BRAF V600-mutant advanced melanoma after over 6 years of follow-up, despite not meeting the initial progression-free survival endpoint.

Clinical Updates news Oncology Respiratory

Enhancing Lung Cancer Screening Adherence: Insights from a Randomized Clinical Trial of Health Communication and Stepped Reminder Interventions

By MedXY 08/12/2026

A landmark randomized trial demonstrates that multilevel stepped reminders targeting both primary care physicians and patients markedly improve adherence to annual lung cancer screening, while health communication alone may be insufficient or counterproductive.

General Surgery news Oncology

Nationwide Evaluation of Robotic Distal Pancreatectomy for Malignancy: Safety, Outcomes, and Comparative Effectiveness in Japan

By MedXY 08/12/2026

This study analyzes nationwide data from Japan comparing robotic, laparoscopic, and open distal pancreatectomy for malignancy, highlighting robotic surgery’s safety and specific perioperative advantages, notably reduced blood loss and conversion rates, though benefits over laparoscopy remain limited.

news OB/GYN & Women's Health Oncology

Menopause Management in Patients with Cancer: A Symptom‑Based, Risk‑Stratified Framework

By MedXY 08/12/2026

Practical, symptom‑focused recommendations for managing menopause in people with cancer—balancing symptom relief with oncologic safety using nonhormonal first-line strategies, selective use of local estrogen, and shared decision making for systemic hormone therapy.

Cardiology news Oncology

Decoding Hepatocellular Carcinoma in Fontan-Associated Liver Disease: Genomic and Transcriptomic Insights

By MedXY 08/12/2026

This article explores the unique genomic and transcriptomic features of hepatocellular carcinoma in Fontan-associated liver disease, revealing distinct mutation patterns and poor-prognosis molecular subtypes that inform disease mechanisms and clinical outcomes.

Diabetes & Endocrinology news Oncology

The Thyroid Cancer Modified Anxiety Scale (TC-MAX): A Novel Tool to Assess Cancer-Related Distress and Guide Patient-Centered Care

By MedXY 08/12/2026

The TC-MAX is the first validated, disease-specific instrument measuring thyroid cancer-related anxiety, showing strong reliability and validity to inform treatment decisions and improve patient-centered care.

Dermatology news Oncology

Dynamic Risk Stratification of Melanocytic Lesions with Peripheral Globules: Insights from a Longitudinal Cohort Study

By MedXY 08/11/2026

Longitudinal monitoring reveals that persistence and growth dynamics of peripheral globules in melanocytic lesions predict melanoma risk more accurately than static features alone, informing tailored surveillance strategies.

news Oncology Otorhinolaryngology

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

By MedXY 08/11/2026

The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.

news OB/GYN & Women’s Health Oncology

Evaluating Androgen Receptor Inhibition Combined with Hormonal Therapies in Recurrent Adult-Type Ovarian Granulosa Cell Tumor: Insights from a Phase II Study

By MedXY 08/11/2026

A Phase II trial assessed the combination of darolutamide, leuprolide acetate, and exemestane in recurrent adult-type ovarian granulosa cell tumor, showing limited objective response but clinically meaningful progression-free survival without severe toxicity.